Preterm Birth Prevention and Management Market to Reach USD 4.49 Billion by 2034, Growing at 10.2% CAGR
The global preterm birth prevention and management market is set for remarkable growth, with its valuation expected to rise from USD 1.70 billion in 2024 to over USD 4.49 billion by 2034. This expansion corresponds to a strong compound annual growth rate (CAGR) of 10.2%, driven by increasing adoption of therapeutics in both developed and developing nations.
Preterm birth remains a leading cause of neonatal mortality and long-term complications. As awareness of this global health challenge grows, governments and healthcare providers are prioritizing interventions to reduce preterm birth rates. Therapeutics such as progesterone supplements, tocolytics, and advanced diagnostic tools are gaining traction for their efficacy in managing and preventing preterm deliveries.
Key factors driving the market’s growth include advancements in maternal-fetal medicine, rising investments in healthcare infrastructure, and supportive policies promoting prenatal care. Emerging markets, in particular, are witnessing higher adoption of these therapies, thanks to improved access to healthcare and growing awareness about the importance of early intervention.
As the market evolves, pharmaceutical companies are focusing on innovative solutions to address unmet needs, such as targeted therapies and non-invasive diagnostic methods. With its critical role in improving maternal and neonatal outcomes, the preterm birth prevention and management market is poised to make significant strides in global healthcare.
Preterm Birth Prevention and Management Market Overview:
Preterm birth prevention and management demand is on the rise since preterm birth has become a key healthcare problem. It is making a significant impact on both disability and perinatal death.
By 2034, there is likely to be a 2.65X surge in the adoption of preterm birth prevention and management. Healthcare professionals are implementing diverse strategies for preventing preterm birth
. This is propelling advancements in the market, with a foreseeable continuation of this trend.
The global trends in the preterm birth prevention and management industry spotlight a shift toward personalized and patient-centric care.
Preterm Birth Prevention and Management Market Trends
The evolving trends in the preterm birth prevention and management market indicate a promising shift toward more personalized and innovative approaches. Healthcare professionals and researchers are taking up a holistic perspective after recognizing the multifaceted nature of preterm birth. Modern diagnostics and customized treatment regimens together represent an important shift from the old one-size-fits-all approach.
Encouraging policies and programs from the government are fostering the development of solutions for managing and preventing preterm births.
There has been a noticeable increase in public and healthcare professional awareness initiatives aimed at educating people about the dangers of preterm birth and available early birth prevention strategies.
Key Growth Drivers
Rising Preterm Birth Rates: The global increase in preterm births has heightened the need for effective prevention and management strategies.
Advancements in Therapeutics: Continued research and development are leading to more effective treatments, including progesterone therapy and corticosteroids, which are critical in managing preterm labor.
Increased Awareness: Growing awareness about maternal and infant health is driving demand for preventive measures against preterm births.
Competitive Landscape
Top companies in the global preterm birth prevention and management market are strategically expanding their global footprint through initiatives like mergers, partnerships, product launches, approvals, collaborations, and acquisitions. These diverse approaches reflect their commitment to addressing preterm birth challenges while positioning themselves as industry leaders. Such dynamic strategies underscore their dedication to advancing healthcare solutions and fostering a broader impact on a global scale.
Recent Developments
The United States Food and Drug Administration authorized Opill®, Perrigo Company plc. announced in July 2023. This over-the-counter (OTC) oral contraceptive is exclusively available for use by adults and is progestin-only. The first birth control pill to be sold over-the-counter in the US was called Opill®.
The United States Food and Drug Administration authorized the Abrysvo (Respiratory Syncytial Virus Vaccine) in August 2023. This is the first vaccination licensed for expectant mothers to prevent severe lower respiratory tract illness (LRTD) and LRTD in babies under six months of age that is caused by the respiratory syncytial virus (RSV).
Key Preterm Birth Prevention and Management Market Players
Aquatic Remedies Pvt. Ltd.
Teva Pharmaceuticals USA, Inc.
Anglo French Drugs & Industries Limited
Biophar Lifesciences Pvt. Ltd.
Jasco Labs (P) Ltd.
BSA Pharma Inc.
Pfizer Inc.
Novartis AG
Sanofi S.A
AMAG Pharmaceuticals
Mylan
Get Full Report Now
